Abstract
Antisecretory drugs are effective antiulcer agents, but its chronic use generates hypergastrinemia and accelerates the development of atrophic gastritis in Helicobacter pylori-positive patients. We have recently shown that gastrin exerts a proinflammatory effect in rats through CCK-2 receptor activation that contributes to the inflammation induced by H. pylori. The present study was designed to examine whether gastrin hypersecretion in response to treatment with antisecretory drugs induces an inflammatory response that could promote mucosal atrophy. The effects of omeprazole or famotidine on leukocyte/endothelial cell interactions in vivo were analyzed in rat mesenteric venules using intravital microscopy. Administration of a single dose of omeprazole or famotidine acutely increased gastrinemia and leukocyte rolling and adhesion, but not emigration into the interstitium. Daily treatment with omeprazole for a short period (3 days) induced a similar response, but when this treatment was extended to 14 days and a steady hyper-gastrinemic state was established, increased leukocyte rolling, adhesion, and emigration was observed. Pretreatment with the CCK-2 receptor antagonist proglumide prevented these inflammatory events in all cases. Leukocytes from rats treated with omeprazole showed increased expression of CD11b/CD18 initially in granulocytes (3-day protocol) and later in monocytes and lymphocytes (14-day protocol). These changes were not observed in animals pretreated with proglumide, and they were not reproduced by incubation of leukocytes from untreated animals in vitro with gastrin. Thus, hypergastrinemia induced by chronic treatment with antisecretory drugs may promote inflammation, which could partly explain their worsening effect in corpus gastritis observed in H. pylori-infected patients.
Footnotes
-
This work was supported by Grants CIBER CD06/04/0071 and C03/02 from Ministerio de Sanidad y Consumo and Grants SAF2004-06211 and SAF2005-01366 from Ministerio de Educación y Cultura, and it was awarded the 2002 prize from Salvat Inquifarma Foundation.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.107.122754.
-
ABBREVIATIONS: PPI, proton pump inhibitor; fMLP, N-formyl-l-methionyl-l-leucyl-l-phenylalanine; PMA, phorbol 12-myristate 13-acetate; PMN, polymorphonuclear neutrophil (polymorphonuclear leukocyte); Ome, omeprazole; Progl, proglumide; Lymph, lymphocyte; Mon, monocyte; L-365,260, (3R)-3(N′-3-methylphenyl) ureido)-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one.
- Received March 16, 2007.
- Accepted July 23, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|